Initial responses to castration therapy are quite favorable, with a significant clinical regression and rapid biochemical responses, as assessed by decline in levels of serum marker, prostate-specific antigen (PSA) in 80–90% of patients with metastatic disease [2, 4, 6]. This evidence concerns the gene KLK3 and metastatic neoplasm.